Since the early death rate in APL patients still reaches 15%, and up to 10% of APL patients are resistant to initial therapy or prone to relapse, further sequencing studies of typical and atypical PML::RARA fusion patients might shed light on the pathophysiology of the disease and its responsiveness to treatment. The gene discussed is RARA; the disease is acute promyelocytic leukemia.